Update offers new functionality to enhance workflows in biologics discovery and cell line development Cambridge, UK, 27 August 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced an updated version of its Cyto-Mine® Studio Software Suite, a collection of software controlling operation of its Cyto-Mine Single Cell Analysis System, data acquisition and follow-up analysis. The latest software version includes new functionality to further enhance users’ workflows in biologics discovery and cell line development.Sphere Fluidics’ Cyto-Mine integrates selective screening of tens of millions of single cells, sorting, dispensing and imaging for clone verification into a single automated platform. The updated Cyto-Mine Studio Software Suite enables all assays to progress automatically from priming to the end of incubation, removing the need for user interaction during these steps. Variable picodroplet generation numbers, ranging from 1–2 million may also be selected, and pooled picodroplet dispensing allows researchers to dispense all sorted picodroplets into a single well, providing more sample for further processing and analysis downstream. It also features a barcode scanner, which is compatible with many barcode systems, to facilitate picodroplet tracking. All data from detected, sorted and dispensed picodroplets are now saved in the local Cyto-Mine database along with experiment configuration parameters and assay results, allowing centralized archiving of experimental data and improved performance of the enhanced data analysis software. Experimental reports summarizing assay results and detailed information on individual picodroplets and their content are also generated.Marian Rehak PhD, Vice-President of R&D at Sphere Fluidics, commented: “The flexibility of Sphere Fluidics’ Cyto-Mine platform makes it suitable for single cell analysis and monoclonality assurance across a variety of application areas. We’re continually striving to improve workflows for researchers and are pleased to introduce the latest version of our Cyto-Mine Studio Software Suite, particularly the pooled picodroplet dispensing functionality which supports the screening of an entire B cell population (obtained from an immunized mouse) twice to allow improved and faster selection of antigen-specific antibodies during antibody discovery.” For more information about the latest version of Sphere Fluidics’ Cyto-Mine Studio Software Suite, please visit: https://spherefluidics.com/new-cyto-mine-functionalities-for-antibody-discovery/ENDSNotes to Editors Cyto-Mine® Studio Software SuiteMarian Rehak PhD, Vice-President of R&D, Sphere Fluidics For high-resolution images please contact Zyme Communications. For further information please contact:Sphere FluidicsDr Zoe NilssonTel: +44 (0)1223 6288982Email: zoe.nilsson@spherefluidics.com Zyme CommunicationsDr Michelle RickettsTel: +44 (0)7789 053885Email: michelle.ricketts@zymecommunications.comAbout Sphere Fluidicswww.spherefluidics.comSphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems for biologics discovery and cell line development.Sphere Fluidics’ Cyto-Mine® System integrates selective screening of tens of millions of single cells, sorting, dispensing, imaging and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run. Cyto-Mine® is underpinned by the Company’s patented, microfluidic picodroplet technology.Sphere Fluidics is located in Granta Park, Cambridgeshire (UK) and Monmouth Junction, New Jersey (USA). The Company has also internationalized its business via a global network of distributors.Follow Sphere Fluidics on Twitter @SphereFluidics and LinkedIn @Sphere Fluidics Limited.